Data favor Merck, Eisai’s Keytruda-Lenvima as the winner in kidney cancer, but window still open for Bristol Myers: analyst
The immuno-oncology data showdown between team Merck and team Bristol Myers Squibb in kidney cancer appears to have a winner in the eyes of at least one analyst. But that doesn’t mean the other party has lost...